GB0128793D0 - Screening method for compounds that modulate neuronal activity - Google Patents

Screening method for compounds that modulate neuronal activity

Info

Publication number
GB0128793D0
GB0128793D0 GBGB0128793.7A GB0128793A GB0128793D0 GB 0128793 D0 GB0128793 D0 GB 0128793D0 GB 0128793 A GB0128793 A GB 0128793A GB 0128793 D0 GB0128793 D0 GB 0128793D0
Authority
GB
United Kingdom
Prior art keywords
compounds
screening method
neuronal activity
modulate neuronal
modulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0128793.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Novartis Forschungsstiftung
Original Assignee
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institut
Novartis Forschungsstiftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research, Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institut, Novartis Forschungsstiftung filed Critical Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Priority to GBGB0128793.7A priority Critical patent/GB0128793D0/en
Publication of GB0128793D0 publication Critical patent/GB0128793D0/en
Priority to AU2002358569A priority patent/AU2002358569A1/en
Priority to US10/497,089 priority patent/US20050019261A1/en
Priority to JP2003547941A priority patent/JP2005510250A/ja
Priority to PCT/EP2002/013519 priority patent/WO2003046552A2/en
Priority to EP02792839A priority patent/EP1459063A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
GBGB0128793.7A 2001-11-30 2001-11-30 Screening method for compounds that modulate neuronal activity Ceased GB0128793D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0128793.7A GB0128793D0 (en) 2001-11-30 2001-11-30 Screening method for compounds that modulate neuronal activity
AU2002358569A AU2002358569A1 (en) 2001-11-30 2002-11-29 Screening method for compounds that modulate neuronal activity
US10/497,089 US20050019261A1 (en) 2001-11-30 2002-11-29 Screening method for compounds that modulate neuronal activity
JP2003547941A JP2005510250A (ja) 2001-11-30 2002-11-29 ニューロン活性を調節する化合物のスクリーニング方法
PCT/EP2002/013519 WO2003046552A2 (en) 2001-11-30 2002-11-29 Screening method for compounds that modulate neuronal activity
EP02792839A EP1459063A2 (en) 2001-11-30 2002-11-29 Screening method for compounds that modulate neuronal activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0128793.7A GB0128793D0 (en) 2001-11-30 2001-11-30 Screening method for compounds that modulate neuronal activity

Publications (1)

Publication Number Publication Date
GB0128793D0 true GB0128793D0 (en) 2002-01-23

Family

ID=9926820

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0128793.7A Ceased GB0128793D0 (en) 2001-11-30 2001-11-30 Screening method for compounds that modulate neuronal activity

Country Status (6)

Country Link
US (1) US20050019261A1 (enExample)
EP (1) EP1459063A2 (enExample)
JP (1) JP2005510250A (enExample)
AU (1) AU2002358569A1 (enExample)
GB (1) GB0128793D0 (enExample)
WO (1) WO2003046552A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658912B2 (en) * 2003-06-20 2010-02-09 University Of Massachusetts Spatial evolution of neural activity
US9018440B2 (en) * 2006-10-27 2015-04-28 Stowers Institute For Medical Research Fluorescent mouse model

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05506990A (ja) * 1990-04-24 1993-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロテアーゼ　ネキシン―２の精製、検出、及び使用方法
US5470970A (en) * 1991-02-28 1995-11-28 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppresing activity
US5777194A (en) * 1995-04-26 1998-07-07 Cephalon, Inc. Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
US6008020A (en) * 1996-10-11 1999-12-28 Human Genome Sciences Brain-associated inhibitor of tissue-type plasminogen activator
CA2345903C (en) * 1998-10-16 2006-09-26 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Molecular pathogenicide mediated plant disease resistance

Also Published As

Publication number Publication date
WO2003046552A2 (en) 2003-06-05
WO2003046552A3 (en) 2003-12-04
EP1459063A2 (en) 2004-09-22
JP2005510250A (ja) 2005-04-21
AU2002358569A1 (en) 2003-06-10
US20050019261A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
AP2004003135A0 (en) Compounds that modulate PPAR activity and methods for their preparation
GB0108959D0 (en) Method for identifying patterns
AU2003272713A8 (en) A method for treating severe tinnitus
GB0213951D0 (en) Screening apparatus
IL164352A0 (en) Methods for treating tweak-related conditions
GB2386713B (en) Apparatus for distributed access control
GB2384874B (en) Apparatus for setting access requirements
AU2003214055A8 (en) Method for screening for compounds having hdac inhibitory activity
IL149148A0 (en) Method for preventing dyskinesias
IL163993A0 (en) Method for treating cognitive disorders
GB0111004D0 (en) Screening method
HUP0201647A3 (en) Screening methods for compounds that affect melanogenesis
AU2001294895A1 (en) Methods for identifying compounds that modulate biofilm activity
AU2002237261A1 (en) Rapid method for screening compounds for in vivo activity
GB9826890D0 (en) Method for screening compounds
AU2002247215A1 (en) Method for screening compounds
IL137371A0 (en) Gene expression methods for screening compounds
GB0128793D0 (en) Screening method for compounds that modulate neuronal activity
EP1376098A4 (en) PROCESS FOR SUBSTANCE ANALYSIS
EP1115549A4 (en) METHOD FOR APPLYING A BSR ELASTOMER
GB9908676D0 (en) Method for screening compounds
IL142533A0 (en) Method for selecting spermatozoon
AU2003206594A8 (en) Screening for modulators of pkng activity
AU4856501A (en) Screening method for compounds
EP1167522A4 (en) BIOMOLECULE ACTIVITY REGULATOR SCREENING METHOD

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)